Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 9;30(16):1731-1740.
doi: 10.1093/eurjpc/zwad197.

Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study

Affiliations

Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study

Xiaoming Jia et al. Eur J Prev Cardiol. .

Abstract

Aims: Interleukin-6 (IL-6) and interleukin-18 (IL-18), important cytokines implicated in atherosclerosis and inflammaging, were assessed for associations with global cardiovascular disease (CVD), atrial fibrillation (AF), and death in older adults.

Methods and results: Participants from Atherosclerosis Risk in Communities study Visit 5 (mean age 75.4 ± 5.1 years) with IL-6 and IL-18 measurements were included (n = 5672). Cox regression models were used to assess associations of IL-6 and IL-18 with coronary heart disease (CHD), ischaemic stroke, heart failure (HF) hospitalization, global CVD (composite of CHD, stroke, and HF), AF, and all-cause death. Over a median follow-up of 7.2 years, there were 1235 global CVD events, 530 AF events, and 1173 deaths. Higher IL-6 [hazard ratio (HR) 1.57, 95% confidence interval (CI) 1.44-1.72 per log unit increase] and IL-18 (HR 1.13, 95% CI 1.01-1.26) were significantly associated with global CVD after adjustment for cardiovascular risk factors. Association between IL-6 and global CVD remained significant after further adjustment for high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin T (hs-TnT) but was no longer significant for IL-18 after further adjustments. Interleukin-6 was also associated with increased risk for CHD, HF, and AF after adjustment for covariates. Both IL-6 and IL-18 were associated with increased risk for all-cause death independent of cardiovascular risk factors and other biomarkers.

Conclusion: Among older adults, both IL-6 and IL-18 were associated with global CVD and death. The association between IL-6 with CVD appears to be more robust and was independent of hs-CRP, NT-proBNP, and hs-TnT.

Keywords: Ageing; Cardiovascular disease; Inflammation; Interleukin-18; Interleukin-6.

Plain language summary

In older adults in the Atherosclerosis Risk in Communities study (average age 75 years), higher levels of interleukin-6 and interleukin-18, two proteins implicated in atherosclerosis and increased inflammation that occurs with ageing, significantly increased risk for global cardiovascular disease (including coronary heart disease, stroke, and heart failure) during the next ∼7 years; interleukin-6 also increased risk for global cardiovascular disease, coronary heart disease, heart failure, and atrial fibrillation even after adjustment for other biomarkers of inflammation and subclinical myocardial injury, and both interleukin-6 and interleukin-18 were associated with increased risk for all-cause death independent of cardiovascular risk factors and other biomarkers. In older adults, higher levels of interleukin-6 and interleukin-18 were both associated with increased risk for global cardiovascular disease (including coronary heart disease, stroke, and heart failure) and death.The association between interleukin-6 and global cardiovascular disease appeared to be stronger than that for interleukin-18 and remained significant after adjustment for other biomarkers of inflammation and subclinical myocardial injury.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Among older adults in the Atherosclerosis Risk in Communities study, both interleukin-6 and interleukin-18 were associated with global cardiovascular disease (coronary heart disease, ischaemic stroke, and heart failure hospitalization) and death. The association of interleukin-18 with cardiovascular disease appears to be mediated by interleukin-6. Abbreviations: AF, atrial fibrillation; ARIC, Atherosclerosis Risk in Communities; CHD, coronary heart disease; CI, confidence interval; CRP, C-reactive protein; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; IL-6, interleukin-6; IL-18, interleukin-18.
Figure 1
Figure 1
Association of interleukin-6 and interleukin-18 with risk for global cardiovascular disease, atrial fibrillation, and total death in older adults. Cox regression analysis adjusted for age, sex, race, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, antihypertensive medication use, diabetes, current smoking, lipid-lowering medication use, prevalent global cardiovascular disease, body mass index, and estimated glomerular filtration rate. Abbreviations: AF, atrial fibrillation; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; IL-6, interleukin-6; IL-18, interleukin-18.
Figure 2
Figure 2
Associations of (A) tertiles of interleukin-6 and (B) tertiles of interleukin-18 with incident cardiovascular outcome events after Visit 5. Cox regression analysis adjusted for age, sex, race, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, antihypertensive medication use, diabetes, current smoking, lipid-lowering medication use, prevalent global cardiovascular disease, body mass index, and estimated glomerular filtration rate. Abbreviations: AF, atrial fibrillation; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; IL-6, interleukin-6; IL-18, interleukin-18.

Comment in

Similar articles

Cited by

References

    1. Williams JW, Huang LH, Randolph GJ. Cytokine circuits in cardiovascular disease. Immunity 2019;50:941–954. - PMC - PubMed
    1. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821–832. - PubMed
    1. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res 2020;126:1260–1280. - PMC - PubMed
    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. . Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–1131. - PubMed
    1. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8:1237–1247. - PMC - PubMed

Publication types

MeSH terms